186 related articles for article (PubMed ID: 36485069)
21. Rs3802278 in 3'-UTR of
Zeng F; Liu Y; Ouyang Q; Sun Z; Zhang K; Li X; Liu Y
J Chemother; 2021 Dec; 33(8):564-569. PubMed ID: 34029511
[TBL] [Abstract][Full Text] [Related]
22. A TGF-β associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer.
Gagno S; Poletto E; Bartoletti M; Quartuccio L; Romualdi C; Garziera M; Scalone S; Sorio R; Dreussi E; Zanusso C; De Mattia E; Roncato R; Cecchin E; Giorda G; De Vita S; Dal Bo M; Puglisi F; Toffoli G
Gynecol Oncol; 2020 Jan; 156(1):233-242. PubMed ID: 31711657
[TBL] [Abstract][Full Text] [Related]
23. [Identification and prognostic value of differentially expressed proteins of patients with platinum resistance epithelial ovarian cancer in serum].
Wu WJ; Wang Q; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2016 Jul; 51(7):515-23. PubMed ID: 27465871
[TBL] [Abstract][Full Text] [Related]
24. Predictive value of ATP7b, BRCA1, BRCA2, PARP1, UIMC1 (RAP80), HOXA9, DAXX, TXN (TRX1), THBS1 (TSP1) and PRR13 (TXR1) genes in patients with epithelial ovarian cancer who received platinum-taxane first-line therapy.
Pontikakis S; Papadaki C; Tzardi M; Trypaki M; Sfakianaki M; Koinis F; Lagoudaki E; Giannikaki L; Kalykaki A; Kontopodis E; Saridaki Z; Malamos N; Georgoulias V; Souglakos J
Pharmacogenomics J; 2017 Dec; 17(6):506-514. PubMed ID: 27779244
[TBL] [Abstract][Full Text] [Related]
25. RNA sequencing and bioinformatics analysis revealed PACSIN3 as a potential novel biomarker for platinum resistance in epithelial ovarian cancer.
Han GH; Shim JE; Yun H; Kim J; Kim JH; Cho H
J Gene Med; 2022 Nov; 24(11):e3452. PubMed ID: 36170157
[TBL] [Abstract][Full Text] [Related]
26. High ATP6V1B1 expression is associated with poor prognosis and platinum‑based chemotherapy resistance in epithelial ovarian cancer.
Han GH; Yun H; Chung JY; Kim JH; Cho H
Oncol Rep; 2023 May; 49(5):. PubMed ID: 36999629
[TBL] [Abstract][Full Text] [Related]
27. Preoperative serum 8-hydroxydeoxyguanosine is associated with chemoresistance and is a powerful prognostic factor in endometrioid-type epithelial ovarian cancer.
Pylväs-Eerola M; Karihtala P; Puistola U
BMC Cancer; 2015 Jul; 15():493. PubMed ID: 26134400
[TBL] [Abstract][Full Text] [Related]
28. Observation of the therapeutic effect of apatinib in advanced platinum-resistant recurrent epithelial ovarian cancer.
Pan Z; Luo Z; He H; Chen Y; Zhao B; Yang Z; Li L
J Ovarian Res; 2023 Feb; 16(1):44. PubMed ID: 36823642
[TBL] [Abstract][Full Text] [Related]
29. Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study.
Farolfi A; Scarpi E; Greco F; Bergamini A; Longo L; Pignata S; Casanova C; Cormio G; Bologna A; Orditura M; Zavallone L; Attademo L; Gallà V; Franzese E; Pigozzi E; Loizzi V; Giorda G; Giardina D; Cioffi R; De Giorgi U
Sci Rep; 2020 Oct; 10(1):18190. PubMed ID: 33097745
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of JARID1B is associated with poor prognosis and chemotherapy resistance in epithelial ovarian cancer.
Wang L; Mao Y; Du G; He C; Han S
Tumour Biol; 2015 Apr; 36(4):2465-72. PubMed ID: 25663457
[TBL] [Abstract][Full Text] [Related]
31. Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism.
Leung D; Price ZK; Lokman NA; Wang W; Goonetilleke L; Kadife E; Oehler MK; Ricciardelli C; Kannourakis G; Ahmed N
J Transl Med; 2022 Dec; 20(1):556. PubMed ID: 36463238
[TBL] [Abstract][Full Text] [Related]
32. Platinum sensitivity and CD133 expression as risk and prognostic predictors of central nervous system metastases in patients with epithelial ovarian cancer.
Liu BL; Liu SJ; Baskys A; Cheng H; Han Y; Xie C; Song H; Li J; Xin XY
BMC Cancer; 2014 Nov; 14():829. PubMed ID: 25399490
[TBL] [Abstract][Full Text] [Related]
33. Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer.
Luo Y; Lee M; Kim HS; Chung HH; Song YS
Medicine (Baltimore); 2016 Sep; 95(36):e4797. PubMed ID: 27603388
[TBL] [Abstract][Full Text] [Related]
34. High expression of CETN2 is associated with platinum resistance and poor prognosis in epithelial ovarian cancer.
Qiu PY; Deng XH; Li L
Clin Transl Oncol; 2023 May; 25(5):1340-1352. PubMed ID: 36527574
[TBL] [Abstract][Full Text] [Related]
35. High claudin-7 expression is associated with a poor response to platinum-based chemotherapy in epithelial ovarian carcinoma.
Kim CJ; Lee JW; Choi JJ; Choi HY; Park YA; Jeon HK; Sung CO; Song SY; Lee YY; Choi CH; Kim TJ; Lee JH; Kim BG; Bae DS
Eur J Cancer; 2011 Apr; 47(6):918-25. PubMed ID: 21134740
[TBL] [Abstract][Full Text] [Related]
36. Tau protein as a potential predictive marker in epithelial ovarian cancer patients treated with paclitaxel/platinum first-line chemotherapy.
Smoter M; Bodnar L; Grala B; Stec R; Zieniuk K; Kozlowski W; Szczylik C
J Exp Clin Cancer Res; 2013 Apr; 32(1):25. PubMed ID: 23631819
[TBL] [Abstract][Full Text] [Related]
37. Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair.
Xiao M; Cai J; Cai L; Jia J; Xie L; Zhu Y; Huang B; Jin D; Wang Z
J Ovarian Res; 2017 Apr; 10(1):24. PubMed ID: 28376831
[TBL] [Abstract][Full Text] [Related]
38. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.
Ratner ES; Keane FK; Lindner R; Tassi RA; Paranjape T; Glasgow M; Nallur S; Deng Y; Lu L; Steele L; Sand S; Muller RU; Bignotti E; Bellone S; Boeke M; Yao X; Pecorelli S; Ravaggi A; Katsaros D; Zelterman D; Cristea MC; Yu H; Rutherford TJ; Weitzel JN; Neuhausen SL; Schwartz PE; Slack FJ; Santin AD; Weidhaas JB
Oncogene; 2012 Oct; 31(42):4559-66. PubMed ID: 22139083
[TBL] [Abstract][Full Text] [Related]
39. Immunohistochemical expression of VEGF predicts response to platinum based chemotherapy in patients with epithelial ovarian cancer.
Siddiqui GK; Maclean AB; Elmasry K; Wong te Fong A; Morris RW; Rashid M; Begent RH; Boxer GM
Angiogenesis; 2011 May; 14(2):155-61. PubMed ID: 21221762
[TBL] [Abstract][Full Text] [Related]
40. Prognostic Value and Implication for Chemotherapy Treatment of ABCB1 in Epithelial Ovarian Cancer: A Meta-Analysis.
Sun S; Cai J; Yang Q; Zhu Y; Zhao S; Wang Z
PLoS One; 2016; 11(11):e0166058. PubMed ID: 27812204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]